{"id":"W2585936581","doi":"10.1007/s10637-017-0438-z","title":"First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors","year":2017,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Ion Channels and Receptors","field":"Neuroscience","cited_by":134,"is_retracted":false,"has_abstract":true,"ca_institutions":"Micropharma (Canada); London Health Sciences Centre; Juravinski Cancer Centre","funders":"National Center for Advancing Translational Sciences","keywords":"Medicine; Adverse effect; Common Terminology Criteria for Adverse Events; Tolerability; Pharmacokinetics; Internal medicine; Toxicity; Response Evaluation Criteria in Solid Tumors; Pharmacodynamics; Anemia; Gastroenterology; Hypokalemia; Asymptomatic; Hypophosphatemia; Neutropenia; Phases of clinical research; Pharmacology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001298983,0.001077498,0.002214293,0.0003488642,0.0005057195,0.0008733798,0.0006600513,0.0007351195,0.004284276],"category_scores_gemma":[0.0004787146,0.0004964491,0.001102589,0.0003689531,0.0007883207,0.0005588244,0.0003008342,0.002404258,0.0008990502],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007972232,"about_ca_system_score_gemma":0.002149331,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000768695,"about_ca_topic_score_gemma":0.00252323,"domain_scores_codex":[0.999599,0.0001418495,0.00001865812,0.0000756739,0.00005053609,0.0001142019],"domain_scores_gemma":[0.9995498,0.00005746317,0.00007026663,0.0000427448,0.00004578642,0.0002338688],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3929257,0.1229176,0.01071118,0.002570784,0.001516312,0.000570623,0.0005949769,0.007059391,0.2367803,0.0007331553,0.01127534,0.2123446],"study_design_scores_gemma":[0.2677503,0.6894445,0.01044075,0.00005262839,0.0004777393,0.0005032271,0.00007764446,0.002266649,0.02102601,0.0002675045,0.007644977,0.00004809271],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9877278,0.002433294,0.001683553,0.0003177141,0.0001277746,0.004101073,0.001653166,0.0002095629,0.001746223],"genre_scores_gemma":[0.9849709,0.001792734,0.003581054,0.0006972958,0.0001370103,0.003264811,0.002191693,0.00006572793,0.003298893],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004284276,"threshold_uncertainty_score":0.01433229,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03587327682816752,"score_gpt":0.3115781625913163,"score_spread":0.2757048857631488,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}